IP Library › Patent Application 17544007
Patent Application
App. No. 17/544,007

METHODS AND COMPOSITIONS FOR DIAGNOSING NEURODEGENERATIVE DISEASE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/544,007
Abstract

Methods and compositions for detecting and diagnosing Parkinson's disease are disclosed.

Claims (29)

1 . A method of diagnosing Parkinson's disease in a subject said method comprising detecting in a biological sample obtained from said subject at least one marker from the C-X-C chemokine receptor type 4 (CXCR-4) or phosphatidylinositol 3-kinase regulatory subunit 1 (alpha) (PIK3R1) signaling pathways,

wherein a modulation in the amount of said marker compared to healthy individuals is indicative of Parkinson's disease.

2 . The method of claim 1 , wherein said marker is selected from the group consisting of PIK3R1, CXCR4, integrin alpha-V (ITGAV), integrin alpha-E (ITGAE), integrin beta-7 (ITGB7), integrin alpha-4 (ITGA4), cluster of differentiation 31 (CD31), secreted phosphoprotein 1 (SPP1), cluster of differentiation 45 (CD45), forkhead box P3 (FoxP3), fibronectin 1 (FN1), CD27, CD4, CD25, CD127, and FAS.

3 . The method of claim 1 , wherein said marker is selected from the group consisting of CD4, CD127, CD25, CD45RA, CD45RO, CD31, FAS, CD27, integrin beta-7, and integrin alpha-4.

4 . The method of claim 1 , wherein said marker is selected from the group consisting of CD45RA, CD45RO, CD31, FAS, integrin beta-7, and integrin alpha-4.

5 . The method of claim 4 , wherein said method comprises detecting at least three of said markers.

6 . The method of claim 1 , wherein the amount of modulation in the amount of said marker correlates to the severity of Parkinson's disease in said patient.

7 . The method of claim 1 , wherein said biological sample is blood.

8 . The method of claim 1 comprising detecting said marker with an antibody immunologically specific for said marker.

9 . The method of claim 1 comprising detecting said marker with a nucleic acid molecule that specifically hybridizes with a nucleic acid molecule encoding said marker.

10 . The method of claim 9 , wherein said nucleic acid molecules are probes or primers.

11 . A method of diagnosing Parkinson's disease in a subject said method comprising detecting effector memory T cells (Tem) in a biological sample obtained from said subject,

wherein an increase in the amount of said Tem compared to healthy individuals is indicative of Parkinson's disease.

12 . The method of claim 11 , wherein the amount of increase in the amount of said Tem correlates to the severity of Parkinson's disease in said patient.

13 . The method of claim 11 , wherein said biological sample is blood.

14 . A method of diagnosing Parkinson's disease in a subject said method comprising measuring the function of regulatory T cells (Treg) in a biological sample obtained from said subject, wherein decreased Treg function is indicative of PD.

15 . The method of claim 14 , wherein the amount of decrease in Treg function correlates to the severity of Parkinson's disease in said patient.

16 . The method of claim 14 , wherein said biological sample is blood.

17 . The method of claim 14 , comprising measuring the ability of said Treg to suppress responder T cell (Tresp) proliferation.

18 . A composition comprising at least one antibody for at least one marker selected from the group consisting of PIK3R1, CXCR4, integrin alpha-V (ITGAV), integrin alpha-E (ITGAE), integrin beta-7 (ITGB7), integrin alpha-4 (ITGA4), cluster of differentiation 31 (CD31), secreted phosphoprotein 1 (SPP1), cluster of differentiation 45 (CD45), forkhead box P3 (FoxP3), fibronectin 1 (FN1), CD27, CD4, CD127, CD25, and FAS.

19 . The composition of claim 18 , wherein said marker is selected from the group consisting of CD4, CD127, CD25, CD45RA, CD45RO, CD31, FAS, CD27, integrin beta-7, and integrin alpha-4.

20 . The composition of claim 18 , wherein said marker is selected from the group consisting of CD45RA, CD45RO, CD31, FAS, integrin beta-7, and integrin alpha-4.

21 . The composition of claim 20 , comprising at least three of said markers.

22 . A composition comprising at least one nucleic acid probe for at least one marker selected from the group consisting of PIK3R1, CXCR4, integrin alpha-V (ITGAV), integrin alpha-E (ITGAE), integrin beta-7 (ITGB7), integrin alpha-4 (ITGA4), cluster of differentiation 31 (CD31), secreted phosphoprotein 1 (SPP1), cluster of differentiation 45 (CD45), forkhead box P3 (FoxP3), fibronectin 1 (FN1), CD27, CD4, CD127. CD25, and FAS.

23 . The composition of claim 22 , wherein said marker is selected from the group consisting of CD4, CD127, CD25, CD45RA, CD45RO, CD31, FAS, CD27, integrin beta-7, and integrin alpha-4.

24 . The composition of claim 22 , wherein said marker is selected from the group consisting of CD45RA, CD45RO, CD31, FAS, integrin beta-7, and integrin alpha-4.

25 . The composition of claim 24 , comprising at least three of said markers.

26 . The composition of claim 22 , wherein said nucleic acid probes are attached to a solid support.

27 . The composition of claim 26 , wherein said solid support comprises up to 100 nucleic acid probes.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2021
From: GENDELMAN, HOWARD; MOSLEY, R LEE; SAUNDERS, JESSICA HUTTER
To: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
Reel/Frame 058445/0719 →